

# Friedemann Paul

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5448003/publications.pdf>

Version: 2024-02-01

480  
papers

27,239  
citations

5896

81  
h-index

10732

138  
g-index

509  
all docs

509  
docs citations

509  
times ranked

20220  
citing authors

#	ARTICLE	IF	CITATIONS
1	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 280.	7.2	686
2	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. <i>Journal of Neuroinflammation</i> , 2012, 9, 14.	7.2	593
3	MRI characteristics of neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2015, 84, 1165-1173.	1.1	523
4	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). <i>Journal of Neurology</i> , 2014, 261, 1-16.	3.6	494
5	A blood based 12-miRNA signature of Alzheimer disease patients. <i>Genome Biology</i> , 2013, 14, R78.	9.6	438
6	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019, 394, 1352-1363.	13.7	433
7	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology, The</i> , 2017, 16, 797-812.	10.2	397
8	A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms. <i>Cell Reports</i> , 2016, 15, 2136-2146.	6.4	371
9	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. <i>Journal of Neuroinflammation</i> , 2016, 13, 279.	7.2	351
10	The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. <i>Neurology</i> , 2016, 86, 2303-2309.	1.1	331
11	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	5.3	315
12	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. <i>Brain</i> , 2019, 142, 1858-1875.	7.6	303
13	Characteristics of Susac syndrome: a review of all reported cases. <i>Nature Reviews Neurology</i> , 2013, 9, 307-316.	10.1	293
14	Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 202-214.	2.5	286
15	Neuromyelitis optica: clinical features, immunopathogenesis and treatment. <i>Clinical and Experimental Immunology</i> , 2014, 176, 149-164.	2.6	277
16	Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2012, 69, 239.	4.5	276
17	Fatigue as a symptom or comorbidity of neurological diseases. <i>Nature Reviews Neurology</i> , 2017, 13, 662-675.	10.1	270
18	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology, The</i> , 2016, 15, 574-584.	10.2	266

#	ARTICLE	IF	CITATIONS
19	MR-elastography reveals degradation of tissue integrity in multiple sclerosis. <i>NeuroImage</i> , 2010, 49, 2520-2525.	4.2	262
20	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	10.2	261
21	The investigation of acute optic neuritis: a review and proposed protocol. <i>Nature Reviews Neurology</i> , 2014, 10, 447-458.	10.1	248
22	No cerebrocervical venous congestion in patients with multiple sclerosis. <i>Annals of Neurology</i> , 2010, 68, 173-183.	5.3	236
23	Neuromyelitis optica. <i>Nature Reviews Disease Primers</i> , 2020, 6, 85.	30.5	232
24	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1005-1015.	1.9	228
25	Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. <i>Brain</i> , 2016, 139, 2641-2652.	7.6	223
26	Cross-reactive CD4 <sup>+</sup> T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. <i>Science</i> , 2021, 374, eabh1823.	12.6	221
27	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. <i>Journal of Neuroinflammation</i> , 2016, 13, 282.	7.2	217
28	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. <i>Frontiers in Neurology</i> , 2020, 11, 501.	2.4	216
29	Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies. <i>JAMA Neurology</i> , 2017, 74, 50.	9.0	214
30	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015, 21, 678-688.	3.0	209
31	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 281.	7.2	202
32	Perivascular spaces—MRI marker of inflammatory activity in the brain?. <i>Brain</i> , 2008, 131, 2332-2340.	7.6	200
33	Brain Viscoelasticity Alteration in Chronic-Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e29888.	2.5	195
34	Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. <i>Frontiers in Neurology</i> , 2018, 9, 888.	2.4	194
35	Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. <i>Neurology</i> , 2012, 79, 708-714.	1.1	190
36	Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica. <i>PLoS Medicine</i> , 2007, 4, e133.	8.4	187

#	ARTICLE	IF	CITATIONS
37	Diagnostic criteria for Susac syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1287-1295.	1.9	184
38	Accuracy and Reliability of the Kinect Version 2 for Clinical Measurement of Motor Function. <i>PLoS ONE</i> , 2016, 11, e0166532.	2.5	183
39	Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. <i>Journal of Neuroinflammation</i> , 2010, 7, 52.	7.2	182
40	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	6.0	173
41	Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. <i>Journal of the Neurological Sciences</i> , 2010, 298, 158-162.	0.6	169
42	Functional and structural brain changes in anti- $\alpha$ -N-methyl-D-aspartate receptor encephalitis. <i>Annals of Neurology</i> , 2013, 74, 284-296.	5.3	167
43	Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e66151.	2.5	162
44	MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 66-72.	2.0	158
45	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. <i>Nature Reviews Neurology</i> , 2018, 14, 199-213.	10.1	157
46	Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Annals of Neurology</i> , 2009, 66, 310-322.	5.3	151
47	The Influence of Physiological Aging and Atrophy on Brain Viscoelastic Properties in Humans. <i>PLoS ONE</i> , 2011, 6, e23451.	2.5	145
48	Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1067-1073.	3.0	144
49	Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1887-1895.	3.0	141
50	Racial differences in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2018, 91, e2089-e2099.	1.1	140
51	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016, 2, e1501678.	10.3	133
52	Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e572.	6.0	133
53	Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1592-1599.	3.0	132
54	Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e334.	6.0	128

#	ARTICLE	IF	CITATIONS
55	Structural Hippocampal Damage Following Anti-N-Methyl-D-Aspartate Receptor Encephalitis. <i>Biological Psychiatry</i> , 2016, 79, 727-734.	1.3	123
56	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	1.9	123
57	Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 1446.	9.0	119
58	Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. <i>Multiple Sclerosis Journal</i> , 2014, 20, 295-303.	3.0	115
59	High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 822-832.	3.7	114
60	Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-10.	0.8	111
61	Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis: an observational study. <i>Lancet Psychiatry</i> , 2017, 4, 768-774.	7.4	111
62	Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2008, 3, e1928.	2.5	110
63	Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. <i>Brain</i> , 2020, 143, 3574-3588.	7.6	110
64	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	2.0	110
65	Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 647-652.	1.4	107
66	Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. <i>Annals of Neurology</i> , 2019, 85, 618-629.	5.3	104
67	Optic Neuritis Is Associated with Inner Nuclear Layer Thickening and Microcystic Macular Edema Independently of Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e71145.	2.5	102
68	Sleep disorders in multiple sclerosis and their relationship to fatigue. <i>Sleep Medicine</i> , 2014, 15, 5-14.	1.6	101
69	Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. <i>Multiple Sclerosis Journal</i> , 2013, 19, 443-450.	3.0	100
70	Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. <i>Journal of Neuroinflammation</i> , 2014, 11, 46.	7.2	100
71	Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1259-1265.	1.9	100
72	Magnetic resonance elastography reveals altered brain viscoelasticity in experimental autoimmune encephalomyelitis. <i>NeuroImage: Clinical</i> , 2012, 1, 81-90.	2.7	99

#	ARTICLE	IF	CITATIONS
73	Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in "pattern II multiple sclerosis" and brain biopsy findings in a MOG-IgG-positive case. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1541-1549.	3.0	96
74	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021, 97, 68-79.	1.1	96
75	Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. <i>EPMA Journal</i> , 2017, 8, 313-325.	6.1	94
76	Uncovering convolutional neural network decisions for diagnosing multiple sclerosis on conventional MRI using layer-wise relevance propagation. <i>NeuroImage: Clinical</i> , 2019, 24, 102003.	2.7	93
77	Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 11, 45-50.	2.0	89
78	Correlation of self-assessed fatigue and alertness in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1134-1140.	3.0	88
79	Worldwide prevalence of neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 555-556.	1.9	87
80	Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e286.	6.0	85
81	Photoreceptor layer thinning in idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1163-1170.	3.9	84
82	Optic radiation damage in multiple sclerosis is associated with visual dysfunction and retinal thinning " an ultrahigh-field MR pilot study. <i>European Radiology</i> , 2015, 25, 122-131.	4.5	84
83	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 261.	7.2	84
84	Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2014, 76, 792-801.	5.3	82
85	Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?. <i>EPMA Journal</i> , 2013, 4, 5.	6.1	80
86	Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 15.	1.6	79
87	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 724-735.	10.2	79
88	Metabolic Changes in the Visual Cortex Are Linked to Retinal Nerve Fiber Layer Thinning in Multiple Sclerosis. <i>PLoS ONE</i> , 2011, 6, e18019.	2.5	76
89	Cerebral magnetic resonance elastography in supranuclear palsy and idiopathic Parkinson's disease. <i>NeuroImage: Clinical</i> , 2013, 3, 381-387.	2.7	76
90	Tracking CNS and systemic sources of oxidative stress during the course of chronic neuroinflammation. <i>Acta Neuropathologica</i> , 2015, 130, 799-814.	7.7	76

#	ARTICLE	IF	CITATIONS
91	Multicenter reliability of semiautomatic retinal layer segmentation using OCT. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e449.	6.0	76
92	Reliability of Intra-Retinal Layer Thickness Estimates. <i>PLoS ONE</i> , 2015, 10, e0137316.	2.5	75
93	Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. <i>EPMA Journal</i> , 2018, 9, 21-33.	6.1	75
94	Sex differences in autoimmune disorders of the central nervous system. <i>Seminars in Immunopathology</i> , 2019, 41, 177-188.	6.1	74
95	Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome. <i>JAMA Neurology</i> , 2018, 75, 1071.	9.0	72
96	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , 2021, 89, 895-910.	5.3	72
97	Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex. <i>Multiple Sclerosis Journal</i> , 2019, 25, 554-564.	3.0	69
98	Attention Network Test reveals alerting network dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 93-99.	3.0	68
99	Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. <i>British Journal of Ophthalmology</i> , 2012, 96, 62-67.	3.9	68
100	Multiple Sclerosis Lesions and Irreversible Brain Tissue Damage. <i>Archives of Neurology</i> , 2012, 69, 739-45.	4.5	68
101	Optic Nerve Head Quantification in Idiopathic Intracranial Hypertension by Spectral Domain OCT. <i>PLoS ONE</i> , 2012, 7, e36965.	2.5	68
102	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020, 56, 102807.	6.1	67
103	Identifying Progression in Multiple Sclerosis: New Perspectives. <i>Annals of Neurology</i> , 2020, 88, 438-452.	5.3	67
104	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 681-686.	1.9	66
105	Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study. <i>Multiple Sclerosis Journal</i> , 2010, 16, 893-896.	3.0	65
106	Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1847-1853.	3.0	65
107	Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2017, 23, 963-972.	3.0	65
108	Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	65

#	ARTICLE	IF	CITATIONS
109	Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 487-495.	4.7	64
110	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	64
111	Exercise in multiple sclerosis – an integral component of disease management. <i>EPMA Journal</i> , 2012, 3, 2.	6.1	63
112	Treatment of sleep disorders may improve fatigue in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1826-1830.	1.4	63
113	Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 411-418.	1.9	63
114	Placebo-controlled study in neuromyelitis optica – Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872.	3.0	63
115	T-cell homeostasis in pediatric multiple sclerosis. <i>Neurology</i> , 2013, 81, 784-792.	1.1	62
116	Multi-scale classification of disease using structural MRI and wavelet transform. <i>NeuroImage</i> , 2012, 62, 48-58.	4.2	61
117	The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. <i>EPMA Journal</i> , 2016, 7, 25.	6.1	61
118	Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. <i>Journal of Neuroinflammation</i> , 2019, 16, 154.	7.2	61
119	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016, 263, 140-149.	3.6	60
120	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	3.0	60
121	Encephalopathy, visual disturbance and hearing loss – recognizing the symptoms of Susac syndrome. <i>Nature Reviews Neurology</i> , 2009, 5, 683-688.	10.1	59
122	Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. <i>EPMA Journal</i> , 2012, 3, 9.	6.1	59
123	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	9.0	59
124	Accuracy and repeatability of two methods of gait analysis – GaitRite, and Mobility Lab, in subjects with cerebellar ataxia. <i>Gait and Posture</i> , 2016, 48, 194-201.	1.4	59
125	Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2016, 22, 160-173.	3.0	59
126	High risk of postpartum relapses in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2017, 89, 2238-2244.	1.1	59

#	ARTICLE	IF	CITATIONS
127	Temporal Retinal Nerve Fiber Loss in Patients with Spinocerebellar Ataxia Type 1. PLoS ONE, 2011, 6, e23024.	2.5	57
128	Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation. Nature Communications, 2019, 10, 217.	12.8	56
129	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e343.	6.0	55
130	Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. Journal of Neurology, 2017, 264, 1370-1380.	3.6	55
131	Superficial white matter damage in anti-NMDA receptor encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 518-525.	1.9	55
132	Ketogenic diet and fasting diet as Nutritional Approaches in Multiple Sclerosis (NAMS): protocol of a randomized controlled study. Trials, 2020, 21, 3.	1.6	55
133	Low 25â€hydroxyvitamin D, but not the bioavailable fraction of 25â€hydroxyvitamin D, is a risk factor for multiple sclerosis. European Journal of Neurology, 2016, 23, 62-67.	3.3	54
134	The chronically inflamed central nervous system provides niches for long-lived plasma cells. Acta Neuropathologica Communications, 2017, 5, 88.	5.2	54
135	Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e446.	6.0	54
136	DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning. PLoS Computational Biology, 2020, 16, e1007616.	3.2	54
137	Breastfeeding is associated with lower risk for multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 553-558.	3.0	53
138	Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. Journal of Neurology, 2016, 263, 575-582.	3.6	53
139	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e204.	6.0	53
140	Cerebral blood perfusion changes in multiple sclerosis. Journal of the Neurological Sciences, 2007, 259, 16-20.	0.6	52
141	Periventricular venous density in multiple sclerosis is inversely associated with T2 lesion count: a 7 Tesla MRI study. Multiple Sclerosis Journal, 2013, 19, 316-325.	3.0	52
142	Safety and preliminary efficacy of deep transcranial magnetic stimulation in MS-related fatigue. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e423.	6.0	52
143	Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS. PLoS ONE, 2012, 7, e38741.	2.5	52
144	What Went Wrong? the Flawed Concept of Cerebrospinal Venous Insufficiency. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 657-668.	4.3	51

#	ARTICLE	IF	CITATIONS
145	The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis. Current Treatment Options in Neurology, 2015, 17, 354.	1.8	51
146	Sex differences in brain atrophy in multiple sclerosis. Biology of Sex Differences, 2020, 11, 49.	4.1	51
147	No Evidence for XMRV in German CFS and MS Patients with Fatigue Despite the Ability of the Virus to Infect Human Blood Cells In Vitro. PLoS ONE, 2010, 5, e15632.	2.5	50
148	Is Metabolic Flexibility Altered in Multiple Sclerosis Patients?. PLoS ONE, 2012, 7, e43675.	2.5	50
149	Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. Neurology, 2015, 85, 610-618.	1.1	50
150	Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. Nature Communications, 2020, 11, 2856.	12.8	50
151	Altered fovea in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	50
152	Dynamics of saccade parameters in multiple sclerosis patients with fatigue. Journal of Neurology, 2012, 259, 2656-2663.	3.6	48
153	Beyond the limbic system: disruption and functional compensation of large-scale brain networks in patients with anti-LGI1 encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1191-1199.	1.9	48
154	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. JAMA Neurology, 2019, 76, 841.	9.0	48
155	Dynamic formation of macular microcysts independent of vitreous traction changes. Neurology, 2014, 83, 73-77.	1.1	47
156	Using perceptive computing in multiple sclerosis - the Short Maximum Speed Walk test. Journal of NeuroEngineering and Rehabilitation, 2014, 11, 89.	4.6	47
157	Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Multiple Sclerosis Journal, 2014, 20, 617-620.	3.0	47
158	Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. Journal of Neurology, 2015, 262, 1379-1384.	3.6	47
159	Widespread inflammation in CLIPPERS syndrome indicated by autopsy and ultra-high-field 7T MRI. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e226.	6.0	47
160	Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e229.	6.0	47
161	Higher-resolution MR elastography reveals early mechanical signatures of neuroinflammation in patients with clinically isolated syndrome. Journal of Magnetic Resonance Imaging, 2016, 44, 51-58.	3.4	47
162	Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. Multiple Sclerosis Journal, 2019, 25, 1926-1936.	3.0	47

#	ARTICLE	IF	CITATIONS
163	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	47
164	MRI Pattern Recognition in Multiple Sclerosis Normal-Appearing Brain Areas. <i>PLoS ONE</i> , 2011, 6, e21138.	2.5	46
165	Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 112.	1.6	46
166	Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis. <i>BMC Neurology</i> , 2014, 14, 31.	1.8	46
167	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a Germanâ€œAustrian retrospective multicenter study in patients with a clinically isolated syndrome. <i>Journal of Neurology</i> , 2016, 263, 2499-2504.	3.6	46
168	Perfluorocarbon Particle Size Influences Magnetic Resonance Signal and Immunological Properties of Dendritic Cells. <i>PLoS ONE</i> , 2011, 6, e21981.	2.5	45
169	Can we overcome the â€œclinico-radiological paradoxâ€™™ in multiple sclerosis?. <i>Journal of Neurology</i> , 2012, 259, 2151-2160.	3.6	45
170	Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2013, 20, 1170-1176.	3.3	45
171	The activity of catechol-O-methyltransferase (COMT) is not impaired by high doses of epigallocatechin-3-gallate (EGCG) in vivo. <i>European Journal of Pharmacology</i> , 2014, 740, 645-651.	3.5	45
172	Can we prevent or treat multiple sclerosis by individualised vitamin D supply?. <i>EPMA Journal</i> , 2013, 4, 4.	6.1	44
173	The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 mice. <i>BMC Neuroscience</i> , 2017, 18, 19.	1.9	44
174	Optical coherence tomography in acute optic neuritis: A population-based study. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 566-573.	2.1	44
175	Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 64-68.	2.0	44
176	Novel uses of retinal imaging with optical coherence tomography in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 31-43.	2.8	44
177	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 262.	7.2	44
178	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. <i>Journal of Neuroinflammation</i> , 2021, 18, 105.	7.2	44
179	Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-Î² Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2013, 8, e70626.	2.5	43
180	Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis. <i>Neurology</i> , 2019, 93, e1439-e1451.	1.1	43

#	ARTICLE	IF	CITATIONS
181	Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features. <i>Frontiers in Neurology</i> , 2019, 10, 608.	2.4	42
182	MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9671-9676.	7.1	42
183	Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1737-1742.	3.0	41
184	Less Is More – Estimation of the Number of Strides Required to Assess Gait Variability in Spatially Confined Settings. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 435.	3.4	41
185	Prodromal headache in MOG-antibody positive optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101965.	2.0	41
186	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	41
187	Identical lesion morphology in primary progressive and relapsing-remitting MS – an ultrahigh field MRI study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1866-1871.	3.0	40
188	Sleep Disorders Reduce Health-Related Quality of Life in Multiple Sclerosis (Nottingham Health) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46 16, 16514-16528.	4.1	40
189	Investigational drugs in development to prevent neuromyelitis optica relapses. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 265-271.	4.1	40
190	Pro-inflammatory Monocyte Phenotype and Cell-Specific Steroid Signaling Alterations in Unmedicated Patients With Major Depressive Disorder. <i>Frontiers in Immunology</i> , 2018, 9, 2693.	4.8	40
191	Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731879668.	1.0	40
192	Comparison of probabilistic tractography and tract-based spatial statistics for assessing optic radiation damage in patients with autoimmune inflammatory disorders of the central nervous system. <i>NeuroImage: Clinical</i> , 2018, 19, 538-550.	2.7	40
193	Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. <i>Therapeutic Advances in Neurological Disorders</i> , 2012, 5, 75-79.	3.5	39
194	Comparison of Standard Versus Wide-Field Composite Images of the Corneal Subbasal Layer by In Vivo Confocal Microscopy. , 2015, 56, 5801.		39
195	Validity of visual perceptive computing for static posturography in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1596-1606.	3.0	39
196	Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis. <i>JAMA Neurology</i> , 2018, 75, 287.	9.0	39
197	SEVERE CARDIAC FAILURE IN A PATIENT WITH MULTIPLE SCLEROSIS FOLLOWING LOW-DOSE MITOXANTRONE TREATMENT. <i>Neurology</i> , 2009, 73, 991-993.	1.1	38
198	MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e259.	6.0	38

#	ARTICLE	IF	CITATIONS
199	Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 78-82.	2.0	38
200	Levetiracetam in Focal Epilepsy and Hepatic Porphyrin: A Case Report. <i>Epilepsia</i> , 2004, 45, 559-560.	5.1	37
201	Low contrast visual acuity testing is associated with cognitive performance in multiple sclerosis: a cross-sectional pilot study. <i>BMC Neurology</i> , 2013, 13, 167.	1.8	37
202	Oxidative damage to mitochondria at the nodes of Ranvier precedes axon degeneration in ex vivo transected axons. <i>Experimental Neurology</i> , 2014, 261, 127-135.	4.1	37
203	Multi-parameter immune profiling of peripheral blood mononuclear cells by multiplexed single-cell mass cytometry in patients with early multiple sclerosis. <i>Scientific Reports</i> , 2019, 9, 19471.	3.3	37
204	Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. <i>Frontiers in Neurology</i> , 2020, 11, 778.	2.4	37
205	Retinal nerve fibre layer thickness correlates with brain white matter damage in multiple sclerosis: A combined optical coherence tomography and diffusion tensor imaging study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1904-1907.	3.0	36
206	Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management. <i>EPMA Journal</i> , 2015, 6, 16.	6.1	36
207	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016, 134, 281-294.	4.2	36
208	Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 198-201.	2.0	36
209	Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging. <i>PLoS ONE</i> , 2018, 13, e0202918.	2.5	36
210	Normative Data and Minimally Detectable Change for Inner Retinal Layer Thicknesses Using a Semi-automated OCT Image Segmentation Pipeline. <i>Frontiers in Neurology</i> , 2019, 10, 1117.	2.4	36
211	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020, 94, e407-e418.	1.1	36
212	Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2235-2251.	3.7	36
213	OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103525.	2.0	36
214	Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. <i>Scientific Reports</i> , 2017, 7, 43718.	3.3	35
215	Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system. <i>EPMA Journal</i> , 2017, 8, 279-294.	6.1	35
216	Multiple sclerosis following etanercept treatment for ankylosing spondylitis. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 397-399.	1.1	34

#	ARTICLE	IF	CITATIONS
217	Fatigue in multiple sclerosis: which patient should be referred to a sleep specialist?. Multiple Sclerosis Journal, 2012, 18, 248-249.	3.0	34
218	Multiple sclerosis: The elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1. Journal of Neuroimmunology, 2014, 272, 56-61.	2.3	34
219	Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization. JAMA Neurology, 2018, 75, 296.	9.0	34
220	Ozanimod for the treatment of relapsing remitting multiple sclerosis. Expert Opinion on Pharmacotherapy, 2018, 19, 2073-2086.	1.8	34
221	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731987158.	1.0	34
222	10th Anniversary of the European Association for Predictive, Preventive and Personalised (3P) Medicine- EPMA World Congress Supplement 2020. EPMA Journal, 2020, 11, 1-133.	6.1	34
223	Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression. Multiple Sclerosis Journal, 2016, 22, 1476-1484.	3.0	33
224	Dynamics and heterogeneity of brain damage in multiple sclerosis. PLoS Computational Biology, 2017, 13, e1005757.	3.2	33
225	Artificial intelligence extension of the OSCAR criteria. Annals of Clinical and Translational Neurology, 2021, 8, 1528-1542.	3.7	33
226	Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon-1a. World Journal of Gastroenterology, 2007, 13, 3638.	3.3	33
227	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. Journal of Neural Transmission, 2016, 123, 439-445.	2.8	32
228	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e339.	6.0	32
229	Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	32
230	Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	32
231	Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	32
232	The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse. Journal of Neuroimmunology, 2013, 262, 66-71.	2.3	31
233	Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies. EPMA Journal, 2018, 9, 249-256.	6.1	31
234	Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 334.	2.4	31

#	ARTICLE	IF	CITATIONS
235	Suggestions for improving the design of clinical trials in multiple sclerosis—results of a systematic analysis of completed phase III trials. <i>EPMA Journal</i> , 2019, 10, 425-436.	6.1	31
236	A woman with acute myelopathy in pregnancy: case outcome. <i>BMJ: British Medical Journal</i> , 2009, 339, b4026-b4026.	2.3	31
237	Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation. <i>Journal of Neuroimmunology</i> , 2013, 254, 165-169.	2.3	30
238	Frequent retinal ganglion cell damage after acute optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 141-147.	2.0	30
239	Increased Retention of Gadolinium in the Inflamed Brain After Repeated Administration of Gadopentetate Dimeglumine. <i>Investigative Radiology</i> , 2019, 54, 617-626.	6.2	30
240	Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry. <i>Scientific Reports</i> , 2021, 11, 13340.	3.3	30
241	Stress-induced brain activity, brain atrophy, and clinical disability in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13444-13449.	7.1	29
242	N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation. <i>Journal of Biological Chemistry</i> , 2020, 295, 17413-17424.	3.4	29
243	Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 450.	2.4	29
244	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. <i>Brain</i> , 2020, 143, 1127-1142.	7.6	29
245	Increased Serum Neurofilament Light and Thin Ganglion Cell—Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	29
246	Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis. <i>PLoS ONE</i> , 2017, 12, e0175279.	2.5	29
247	Maximum walking speed in multiple sclerosis assessed with visual perceptive computing. <i>PLoS ONE</i> , 2017, 12, e0189281.	2.5	29
248	Environmental factors in early childhood are associated with multiple sclerosis: a case-control study. <i>BMC Neurology</i> , 2011, 11, 123.	1.8	27
249	Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 196.	7.2	27
250	High-dose vitamin D supplementation in multiple sclerosis — results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732090347.	1.0	27
251	Multimodal Retinal Vessel Analysis in CADASIL Patients. <i>PLoS ONE</i> , 2014, 9, e112311.	2.5	26
252	Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102485.	2.0	26

#	ARTICLE	IF	CITATIONS
253	Assessing Mitochondrial Movement Within Neurons: Manual Versus Automated Tracking Methods. <i>Traffic</i> , 2015, 16, 906-917.	2.7	25
254	RETINAL LESION EVOLUTION IN SUSAC SYNDROME. <i>Retina</i> , 2016, 36, 366-374.	1.7	25
255	Evaluation of the "ring sign"™ and the "core sign"™ as a magnetic resonance imaging marker of disease activity and progression in clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732091548.	1.0	25
256	The German healthcare system. <i>EPMA Journal</i> , 2010, 1, 535-547.	6.1	24
257	Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. <i>Journal of Neuroinflammation</i> , 2014, 11, 129.	7.2	24
258	Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. <i>Neurology</i> , 2015, 85, 521-527.	1.1	24
259	Signaling networks in MS: A systems-based approach to developing new pharmacological therapies. <i>Multiple Sclerosis Journal</i> , 2015, 21, 138-146.	3.0	24
260	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). <i>Journal of Neurology</i> , 2019, 266, 386-397.	3.6	24
261	Clinical and neuroimaging findings in MOGAD—MRI and OCT. <i>Clinical and Experimental Immunology</i> , 2021, 206, 266-281.	2.6	24
262	Magnetic resonance imaging findings at the first episode of acute optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 30-36.	2.0	23
263	A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 330-338.	1.9	23
264	Low-Density Granulocytes Are a Novel Immunopathological Feature in Both Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Immunology</i> , 2019, 10, 2725.	4.8	23
265	Imaging the Visual Pathway in Neuromyelitis Optica. <i>Multiple Sclerosis International</i> , 2011, 2011, 1-5.	0.8	22
266	Enlargement of Cerebral Ventricles as an Early Indicator of Encephalomyelitis. <i>PLoS ONE</i> , 2013, 8, e72841.	2.5	22
267	Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 49.	10.8	22
268	<i>Toxoplasma gondii</i> seropositivity is negatively associated with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 285, 119-124.	2.3	22
269	Metabolic, Mental and Immunological Effects of Normoxic and Hypoxic Training in Multiple Sclerosis Patients: A Pilot Study. <i>Frontiers in Immunology</i> , 2018, 9, 2819.	4.8	22
270	Gadolinium in human brain sections and colocalization with other elements. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e515.	6.0	22

#	ARTICLE	IF	CITATIONS
271	No Evidence for Retinal Damage Evolving from Reduced Retinal Blood Flow in Carotid Artery Disease. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	21
272	Association of serum Epstein-Barr nuclear antigen-1 antibodies and intrathecal immunoglobulin synthesis in early multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 285, 156-160.	2.3	21
273	Visual dysfunction, but not retinal thinning, following anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e198.	6.0	21
274	Brain activity, regional gray matter loss, and decision-making in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1163-1173.	3.0	21
275	Mitoxantrone Induces Natural Killer Cell Maturation in Patients with Secondary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e39625.	2.5	21
276	Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2007, 16, 479-484.	2.0	20
277	Higher macular volume in patients with MS receiving fingolimod. <i>Neurology</i> , 2013, 80, 128-129.	1.1	20
278	7T MRI in natalizumab-associated PML and ongoing MS disease activity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e171.	6.0	20
279	Longitudinal Intravital Imaging of the Retina Reveals Long-term Dynamics of Immune Infiltration and Its Effects on the Glial Network in Experimental Autoimmune Uveoretinitis, without Evident Signs of Neuronal Dysfunction in the Ganglion Cell Layer. <i>Frontiers in Immunology</i> , 2016, 7, 642.	4.8	20
280	Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1156-1164.	1.9	20
281	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	20
282	Longitudinal Retinal Changes in MOGAD. <i>Annals of Neurology</i> , 2022, 92, 476-485.	5.3	20
283	SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 960-971.	1.9	20
284	Olfactory Dysfunction in Patients with Neuromyelitis Optica. <i>Multiple Sclerosis International</i> , 2013, 2013, 1-4.	0.8	19
285	Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e338.	6.0	19
286	Quantitative Multi-Parameter Mapping Optimized for the Clinical Routine. <i>Frontiers in Neuroscience</i> , 2020, 14, 611194.	2.8	19
287	Optical coherence tomography for retinal imaging in multiple sclerosis. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2014, 4, 153.	1.3	18
288	Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1. <i>PLoS ONE</i> , 2015, 10, e0130251.	2.5	18

#	ARTICLE	IF	CITATIONS
289	Subjective and objective assessment of physical activity in multiple sclerosis and their relation to health-related quality of life. <i>BMC Neurology</i> , 2017, 17, 10.	1.8	18
290	Inflammation-induced brain endothelial activation leads to uptake of electrostatically stabilized iron oxide nanoparticles via sulfated glycosaminoglycans. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1411-1421.	3.3	18
291	Association Between Fatigue and Motor Exertion in Patients With Multiple Sclerosis—a Prospective Study. <i>Frontiers in Neurology</i> , 2020, 11, 208.	2.4	18
292	Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 377-383.	1.9	18
293	Postural hand tremor before and following liver transplantation and immunosuppression with cyclosporine or tacrolimus in patients without clinical signs of hepatic encephalopathy. <i>Clinical Transplantation</i> , 2004, 18, 429-433.	1.6	17
294	Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. <i>Neurology</i> , 2013, 81, 1966-1966.	1.1	17
295	Detailing intra-lesional venous lumen shrinking in multiple sclerosis investigated by sFLAIR MRI at 7-T. <i>Journal of Neurology</i> , 2014, 261, 2032-2036.	3.6	17
296	Increased Catabolic State in Spinocerebellar Ataxia Type 1 Patients. <i>Cerebellum</i> , 2014, 13, 440-446.	2.5	17
297	Poor Sleep in Multiple Sclerosis Correlates with Beck Depression Inventory Values, but Not with Polysomnographic Data. <i>Sleep Disorders</i> , 2016, 2016, 1-5.	1.4	17
298	Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1131-1139.	2.8	17
299	Vision and Vision-Related Measures in Progressive Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 455.	2.4	17
300	Impact of treatment on cellular immunophenotype in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	17
301	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 192-202.	5.3	17
302	Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration. <i>PLoS ONE</i> , 2015, 10, e0128386.	2.5	16
303	Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder. <i>European Radiology</i> , 2017, 27, 2206-2215.	4.5	16
304	CuBe: parametric modeling of 3D foveal shape using cubic Bézier. <i>Biomedical Optics Express</i> , 2017, 8, 4181.	2.9	16
305	Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. <i>Journal of Neuroinflammation</i> , 2017, 14, 172.	7.2	16
306	Brain Iron and Metabolic Abnormalities in C19orf12 Mutation Carriers: A 7.0 Tesla MRI Study in Mitochondrial Membrane Protein-associated Neurodegeneration. <i>Movement Disorders</i> , 2020, 35, 142-150.	3.9	16

#	ARTICLE	IF	CITATIONS
307	Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	16
308	C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD. <i>Journal of Neuroimmunology</i> , 2021, 360, 577699.	2.3	16
309	A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110143.	3.5	16
310	Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly. <i>Journal of Immunology</i> , 2022, 208, 1001-1005.	0.8	16
311	Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. <i>Neurochemistry International</i> , 2010, 57, 662-667.	3.8	15
312	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , 2015, 39, 601-608.	1.3	15
313	Synapsin-antibodies in psychiatric and neurological disorders: Prevalence and clinical findings. <i>Brain, Behavior, and Immunity</i> , 2017, 66, 125-134.	4.1	15
314	The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis. <i>Journal of Neuro-Ophthalmology</i> , 2018, 38, 494-501.	0.8	15
315	Temporal visual resolution and disease severity in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e492.	6.0	15
316	Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study. <i>Brain Communications</i> , 2019, 1, fcz026.	3.3	15
317	Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e541.	6.0	15
318	Contactless recording of sleep apnea and periodic leg movements by nocturnal 3-D-video and subsequent visual perceptive computing. <i>Scientific Reports</i> , 2019, 9, 16812.	3.3	15
319	Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1061-1072.	3.1	15
320	Vitamin D and Disease Severity in Multiple Sclerosis—Baseline Data From the Randomized Controlled Trial (EVIDIMS). <i>Frontiers in Neurology</i> , 2020, 11, 129.	2.4	15
321	Association of a Marker of <i>N</i> -Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration. <i>JAMA Neurology</i> , 2021, 78, 842.	9.0	15
322	Revised diagnostic criteria for neuromyelitis optica—incorporation of NMO-IgG status. <i>Nature Clinical Practice Neurology</i> , 2007, 3, E1-E1.	2.5	15
323	B-mode ultrasound assessment of pupillary function: Feasibility, reliability and normal values. <i>PLoS ONE</i> , 2017, 12, e0189016.	2.5	15
324	Metabolic Evidence for Cerebral Neurodegeneration in Spinocerebellar Ataxia Type 1. <i>Cerebellum</i> , 2014, 13, 199-206.	2.5	14

#	ARTICLE	IF	CITATIONS
325	Chronic cerebrospinal venous insufficiency in multiple sclerosis: the final curtain. <i>Lancet, The</i> , 2014, 383, 106-108.	13.7	14
326	Studying Axonal Outgrowth and Regeneration of the Corticospinal Tract in Organotypic Slice Cultures. <i>Journal of Neurotrauma</i> , 2015, 32, 1465-1477.	3.4	14
327	Pushing the boundaries of neuromyelitis optica. <i>Neurology</i> , 2015, 85, 118-119.	1.1	14
328	MRI Markers and Functional Performance in Patients With CIS and MS: A Cross-Sectional Study. <i>Frontiers in Neurology</i> , 2018, 9, 718.	2.4	14
329	VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e475.	6.0	14
330	7 Tesla MRI of Balo's concentric sclerosis versus multiple sclerosis lesions. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 900-912.	3.7	14
331	Conduction delays in the visual pathways of progressive multiple sclerosis patients covary with brain structure. <i>NeuroImage</i> , 2020, 221, 117204.	4.2	14
332	Emerging drugs for the treatment of neuromyelitis optica. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 285-297.	2.4	14
333	Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102579.	2.0	14
334	Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study. <i>Frontiers in Neurology</i> , 2020, 11, 499910.	2.4	14
335	Foveal changes in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive. <i>European Journal of Neurology</i> , 2021, 28, 2280-2293.	3.3	14
336	Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2016, 113, 879-886.	0.9	14
337	An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2020, 22, 226-232.	1.0	14
338	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease. <i>Neurology</i> , 2022, 98, .	1.1	14
339	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1859-1870.	3.0	14
340	Hope for a rare disease: eculizumab in neuromyelitis optica. <i>Lancet Neurology, The</i> , 2013, 12, 529-531.	10.2	13
341	Are there Epstein-Barr virus seronegative patients with multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1242-1243.	3.0	13
342	Periodic limb movements during REM sleep in multiple sclerosis: a previously undescribed entity. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 2323.	2.2	13

#	ARTICLE	IF	CITATIONS
343	Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency. <i>Journal of Neurology</i> , 2015, 262, 1927-1935.	3.6	13
344	Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod. <i>Case Reports in Neurological Medicine</i> , 2016, 2016, 1-8.	0.4	13
345	Olfactory dysfunction in patients with primary progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e369.	6.0	13
346	MRI-Based Methods for Spinal Cord Atrophy Evaluation: A Comparison of Cervical Cord Cross-Sectional Area, Cervical Cord Volume, and Full Spinal Cord Volume in Patients with Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders. <i>American Journal of Neuroradiology</i> , 2018, 39, 1362-1368.	2.4	13
347	Transient enlargement of brain ventricles during relapsing-remitting multiple sclerosis and experimental autoimmune encephalomyelitis. <i>JCI Insight</i> , 2020, 5, .	5.0	13
348	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 188-195.	1.9	13
349	CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage. <i>Journal of Neuroinflammation</i> , 2022, 19, 86.	7.2	13
350	Treatment-resistant chronic headaches and focal pachymeningitis in a 46-year-old man: a rare presentation of Wegener's granulomatosis. <i>Lancet Neurology</i> , The, 2008, 7, 368-372.	10.2	12
351	Vessel Labeling in Combined Confocal Scanning Laser Ophthalmoscopy and Optical Coherence Tomography Images: Criteria for Blood Vessel Discrimination. <i>PLoS ONE</i> , 2014, 9, e102034.	2.5	12
352	Effects of Deep Repetitive Transcranial Magnetic Stimulation on Brain-Derived Neurotrophic Factor Serum Concentration in Healthy Volunteers. <i>Neuropsychobiology</i> , 2014, 69, 112-119.	1.9	12
353	Altered paired associative stimulation-induced plasticity in NMDAR encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 101-113.	3.7	12
354	Association of smoking but not HLA-DRB1*15:01, <i>APOE</i> or body mass index with brain atrophy in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 661-668.	3.0	12
355	Epigallocatechin Gallate in Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	12
356	Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2180-2190.	3.0	12
357	Fatigue in multiple sclerosis: a diagnostic and therapeutic challenge. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 791-793.	1.8	11
358	Fine specificity of the antibody response to Epstein-Barr nuclear antigen-2 and other Epstein-Barr virus proteins in patients with clinically isolated syndrome: A peptide microarray-based case-control study. <i>Journal of Neuroimmunology</i> , 2016, 297, 56-62.	2.3	11
359	Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders. <i>Acta Neurologica Belgica</i> , 2020, 120, 223-225.	1.1	11
360	Is APOE $\epsilon$ 4 associated with cognitive performance in early MS?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e728.	6.0	11

#	ARTICLE	IF	CITATIONS
361	Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102027.	2.0	11
362	Antibody signatures in patients with histopathologically defined multiple sclerosis patterns. <i>Acta Neuropathologica</i> , 2020, 139, 547-564.	7.7	11
363	Pain, depression, and quality of life in adults with MOCâ€“antibodyâ€“associated disease. <i>European Journal of Neurology</i> , 2021, 28, 1645-1658.	3.3	11
364	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	3.0	11
365	Transdiagnostic hippocampal damage patterns in neuroimmunological disorders. <i>NeuroImage: Clinical</i> , 2020, 28, 102515.	2.7	11
366	Active contour method for ILM segmentation in ONH volume scans in retinal OCT. <i>Biomedical Optics Express</i> , 2018, 9, 6497.	2.9	11
367	State-dependent signatures of anti- <i>N</i> -methyl-D-aspartate receptor encephalitis. <i>Brain Communications</i> , 2022, 4, fcab298.	3.3	11
368	Temporal retinal nerve fibre layer thinning in cluster headache patients detected by optical coherence tomography. <i>Cephalgia</i> , 2015, 35, 946-958.	3.9	10
369	Omics-Based Approach Reveals Complement-Mediated Inflammation in Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS). <i>Frontiers in Immunology</i> , 2018, 9, 741.	4.8	10
370	EMR-integrated minimal core dataset for routine health care and multiple research settings: A case study for neuroinflammatory demyelinating diseases. <i>PLoS ONE</i> , 2019, 14, e0223886.	2.5	10
371	Blunted neural and psychological stress processing predicts future grey matter atrophy in multiple sclerosis. <i>Neurobiology of Stress</i> , 2020, 13, 100244.	4.0	10
372	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	1.9	10
373	Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) â€“ preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial. <i>BMC Neurology</i> , 2020, 20, 75.	1.8	10
374	Modular deep neural networks for automatic quality control of retinal optical coherence tomography scans. <i>Computers in Biology and Medicine</i> , 2022, 141, 104822.	7.0	10
375	<i>In vivo</i> detection of teriflunomide-derived fluorine signal during neuroinflammation using fluorine MR spectroscopy. <i>Theranostics</i> , 2021, 11, 2490-2504.	10.0	10
376	Teriflunomide Preserves Neuronal Activity and Protects Mitochondria in Brain Slices Exposed to Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1538.	4.1	10
377	Bilateral meralgia paresthetica after cesarian section with epidural analgesia. <i>Journal of the Peripheral Nervous System</i> , 2006, 11, 98-99.	3.1	9
378	Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study. <i>PLoS ONE</i> , 2016, 11, e0147968.	2.5	9

#	ARTICLE	IF	CITATIONS
379	Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0T MRI clinical study. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2016, 29, 535-541.	2.0	9
380	What should a person with relapsing-remitting multiple sclerosis know? " Focus group and survey data of a risk knowledge questionnaire (RIKNO 2.0). <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 186-195.	2.0	9
381	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020, 11, 579438.	2.4	9
382	Visual system damage and network maladaptation are associated with cognitive performance in neuromyelitis optica spectrum disorders.. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102406.	2.0	9
383	Teriflunomide preserves peripheral nerve mitochondria from oxidative stress-mediated alterations. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232094477.	2.5	9
384	Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders. <i>European Radiology</i> , 2020, 30, 5048-5058.	4.5	9
385	The Worm-Specific Immune Response in Multiple Sclerosis Patients Receiving Controlled <i>Trichuris suis</i> Ova Immunotherapy. <i>Life</i> , 2021, 11, 101.	2.4	9
386	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study. <i>NeuroImage: Clinical</i> , 2021, 30, 102608.	2.7	9
387	Pregnancy in Multiple Sclerosis: A Questionnaire Study. <i>PLoS ONE</i> , 2014, 9, e99106.	2.5	9
388	In vivo stiffness of multiple sclerosis lesions is similar to that of normal-appearing white matter. <i>Acta Biomaterialia</i> , 2022, 138, 410-421.	8.3	9
389	Efficacy of vision restoration therapy after optic neuritis (VISION study): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 94.	1.6	8
390	Tumefactive multiple sclerosis and fingolimod. <i>Neurology</i> , 2013, 81, 1648-1649.	1.1	8
391	Complement regulatory proteins (CD46, 55 and 59) expressed on Schwann cells: Immune targets in demyelinating neuropathies?. <i>Journal of Neuroimmunology</i> , 2014, 276, 172-174.	2.3	8
392	Effects of diazoxide in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e147.	6.0	8
393	Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study. <i>BMC Neurology</i> , 2015, 15, 265.	1.8	8
394	Alzheimer's disease: Elevated pigment epithelium-derived factor in the cerebrospinal fluid is mostly of systemic origin. <i>Journal of the Neurological Sciences</i> , 2017, 375, 123-128.	0.6	8
395	Self-perception and determinants of color vision in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 145-152.	2.8	8
396	Instrumental Assessment of Stepping in Place Captures Clinically Relevant Motor Symptoms of Parkinson's Disease. <i>Sensors</i> , 2020, 20, 5465.	3.8	8

#	ARTICLE	IF	CITATIONS
397	Aggressive multiple sclerosis: a matter of measurement and timing. <i>Brain</i> , 2020, 143, e97-e97.	7.6	8
398	Cortical topological network changes following optic neuritis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e687.	6.0	8
399	Magnetic resonance T1w/T2w ratio in the middle cerebellar peduncle might be a sensitive biomarker for multiple system atrophy. <i>European Radiology</i> , 2021, 31, 4277-4284.	4.5	8
400	Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry. <i>Multiple Sclerosis Journal</i> , 2022, 28, 865-871.	3.0	8
401	Optic nerve head three-dimensional shape analysis. <i>Journal of Biomedical Optics</i> , 2018, 23, 1.	2.6	8
402	Leptomeningeal and Intraparenchymal Blood Barrier Disruption in a MOG-IgG-Positive Patient. <i>Case Reports in Neurological Medicine</i> , 2018, 2018, 1-3.	0.4	7
403	Olfactory and Gustatory Dysfunction in Patients With Autoimmune Encephalitis. <i>Frontiers in Neurology</i> , 2019, 10, 480.	2.4	7
404	Genetic determinants of the humoral immune response in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e827.	6.0	7
405	Functionally Relevant Maculopathy and Optic Atrophy in Spinocerebellar Ataxia Type 1. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 502-508.	1.5	7
406	Considerations for Mean Upper Cervical Cord Area Implementation in a Longitudinal MRI Setting: Methods, Interrater Reliability, and MRI Quality Control. <i>American Journal of Neuroradiology</i> , 2020, 41, 343-350.	2.4	7
407	Retinal Thickness Analysis in Progressive Multiple Sclerosis Patients Treated With Epigallocatechin Gallate: Optical Coherence Tomography Results From the SUPREMES Study. <i>Frontiers in Neurology</i> , 2021, 12, 615790.	2.4	7
408	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103080.	2.0	7
409	Retinal optical coherence tomography and magnetic resonance imaging in neuromyelitis optica spectrum disorders and MOG-antibody associated disorders: an updated review. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1101-1123.	2.8	7
410	Neural Processes of Psychological Stress and Relaxation Predict the Future Evolution of Quality of Life in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 753107.	2.4	7
411	Different Impact of Gadopentetate and Gadobutrol on Inflammation-Promoted Retention and Toxicity of Gadolinium Within the Mouse Brain. <i>Investigative Radiology</i> , 2022, 57, 677-688.	6.2	7
412	Intraretinal Layer Segmentation Using Cascaded Compressed U-Nets. <i>Journal of Imaging</i> , 2022, 8, 139.	3.0	7
413	AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110068.	1.0	6
414	Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells. <i>Neurotherapeutics</i> , 2021, 18, 1783-1797.	4.4	6

#	ARTICLE	IF	CITATIONS
415	Characteristics of secondary progressive multiple sclerosis: Disease activity and provision of care in Germany – A registry-based/multicentric cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103281.	2.0	6
416	A woman with acute myelopathy in pregnancy: case presentation. <i>BMJ: British Medical Journal</i> , 2009, 339, b3862-b3862.	2.3	6
417	Afferent Visual Pathway Affection in Patients with PMP22 Deletion-Related Hereditary Neuropathy with Liability to Pressure Palsies. <i>PLoS ONE</i> , 2016, 11, e0164617.	2.5	6
418	Frailty and Falls in People Living With Multiple Sclerosis. <i>Archives of Physical Medicine and Rehabilitation</i> , 2022, 103, 952-957.	0.9	6
419	Immune signature of multiple sclerosis-associated depression. <i>Brain, Behavior, and Immunity</i> , 2022, 100, 174-182.	4.1	6
420	Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon. <i>Journal of the Neurological Sciences</i> , 2018, 387, 60-69.	0.6	5
421	Wisdom of the expert crowd prediction of response for 3 neurology randomized trials. <i>Neurology</i> , 2020, 95, e488-e498.	1.1	5
422	Cognitive Impairment in Multiple System Atrophy Is Related to White Matter Damage Detected by the T1-Weighted/T2-Weighted Ratio. <i>European Neurology</i> , 2021, 84, 435-443.	1.4	5
423	Identification of the gliogenic state of human neural stem cells to optimize in vitro astrocyte differentiation. <i>Journal of Neuroscience Methods</i> , 2021, 361, 109284.	2.5	5
424	Prefrontal-amygdala emotion regulation and depression in multiple sclerosis. <i>Brain Communications</i> , 2022, 4, .	3.3	5
425	Is It Too Early to Predict the Failure of Natalizumab in NMO? – Reply. <i>Archives of Neurology</i> , 2012, 69, 1085.	4.5	4
426	Bilateral vertebral artery dissection, agenesis of both ICAs, and connective tissue aberrations. <i>Neurology</i> , 2013, 80, 1442-1443.	1.1	4
427	Concomitant amyotrophic lateral sclerosis and paraclinical laboratory features of multiple sclerosis: coincidence or causal relationship?. <i>BMJ Case Reports</i> , 2013, 2013, bcr2012007975-bcr2012007975.	0.5	4
428	Optimal management of multiple sclerosis during pregnancy: current perspectives. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2014, 4, 111.	1.3	4
429	Objective assessment of a relative afferent pupillary defect by B-mode ultrasound. <i>PLoS ONE</i> , 2018, 13, e0202774.	2.5	4
430	Neural mechanisms of perceptual decision-making and their link to neuropsychiatric symptoms in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 139-145.	2.0	4
431	Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis. <i>Scientific Reports</i> , 2020, 10, 8776.	3.3	4
432	Longitudinal ultra-high field MRI of brain lesions in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102066.	2.0	4

#	ARTICLE	IF	CITATIONS
433	Practical recognition tools of immunoglobulin G serum antibodies against the myelin oligodendrocyte glycoprotein in optic neuritis and its clinical implications. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 42-53.	1.0	4
434	Cultural bias in motor function patterns: Potential relevance for predictive, preventive, and personalized medicine. <i>EPMA Journal</i> , 2021, 12, 91-101.	6.1	4
435	Autoantibodies to tetraspanins (CD9, CD81 and CD82) in demyelinating diseases. <i>Journal of Neuroimmunology</i> , 2016, 291, 78-81.	2.3	3
436	Altered Coupling of Psychological Relaxation and Regional Volume of Brain Reward Areas in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 568850.	2.4	3
437	Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1628-1641.	3.7	3
438	Investigation of Visual System Involvement in Spinocerebellar Ataxia Type 14. <i>Cerebellum</i> , 2020, 19, 469-482.	2.5	3
439	Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	3
440	Accelerating clinical research in neuromyelitis optica spectrum disorders. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 89-91.	1.0	3
441	Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity. <i>Neurodegenerative Disease Management</i> , 2021, 11, 143-153.	2.2	3
442	Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2022, 28, 757-767.	3.0	3
443	N2 year in review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e925.	6.0	3
444	Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103466.	2.0	3
445	Patch individual filter layers in CNNs to harness the spatial homogeneity of neuroimaging data. <i>Scientific Reports</i> , 2021, 11, 24447.	3.3	3
446	Prediction of high and low disease activity in early MS patients using multiple kernel learning identifies importance of lateral ventricle intensity. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732211097.	1.0	3
447	Progressive multiple sclerosis: desperately seeking remedy. <i>Lancet Neurology</i> , The, 2013, 12, 840-841.	10.2	2
448	Reply to: Photoreceptor layer thinning in Parkinsonian syndromes. <i>Movement Disorders</i> , 2014, 29, 1223-1224.	3.9	2
449	Higher-resolution MR elastography reveals early mechanical signatures of neuroinflammation in patients with clinically isolated syndrome. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, spcone-spcone.	3.4	2
450	Retinal imaging and axonal degeneration in later onset multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 370, 1-6.	0.6	2

#	ARTICLE	IF	CITATIONS
451	The effectiveness of acupuncture and mindfulness-based stress reduction (MBSR) for patients with multiple sclerosis associated fatigue – A study protocol and its rationale for a randomized controlled trial. <i>European Journal of Integrative Medicine</i> , 2018, 20, 6-15.	1.7	2
452	Binding patterns and functional properties of human antibodies to AQP4 and MOG on murine optic nerve and retina. <i>Journal of Neuroimmunology</i> , 2020, 342, 577194.	2.3	2
453	Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD – Commentary. <i>Multiple Sclerosis Journal</i> , 2021, 27, 16-18.	3.0	2
454	Simultaneous T2 and mapping of multiple sclerosis lesions with radial RARE-EPI. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 1383-1402.	3.0	2
455	A woman with acute myelopathy in pregnancy: case progression. <i>BMJ: British Medical Journal</i> , 2009, 339, b4025-b4025.	2.3	2
456	Automatic quality evaluation as assessment standard for optical coherence tomography. , 2019, , .		2
457	Proposal for Post Hoc Quality Control in Instrumented Motion Analysis Using Markerless Motion Capture: Development and Usability Study. <i>JMIR Human Factors</i> , 2022, 9, e26825.	2.0	2
458	Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry. <i>Neurology and Therapy</i> , 2022, 11, 319-336.	3.2	2
459	Anatomical and functional visual network patterns in progressive multiple sclerosis. <i>Human Brain Mapping</i> , 2022, 43, 1590-1597.	3.6	2
460	Preventing Axonal Sodium Overload or Mitochondrial Calcium Uptake Protects Axonal Mitochondria from Oxidative Stress-Induced Alterations. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-13.	4.0	2
461	Cladribine in multiple sclerosis: pitfalls in a new treatment landscape. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1-3.	1.8	1
462	Retinal Segmentation to Demonstrate Hyperplasia in Ataxia of Charlevoix-Saguenay: Critique on Study Methodology and Results. , 2014, 55, 4728.		1
463	Single-subject independent component analysis-based intensity normalization in non-quantitative multi-modal structural MRI. <i>Human Brain Mapping</i> , 2017, 38, 3615-3622.	3.6	1
464	Pursuing functional connectivity in NMDAR1 autoantibody carriers – Authors' reply. <i>Lancet Psychiatry</i> , 2018, 5, 22.	7.4	1
465	Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy. <i>BMC Neurology</i> , 2019, 19, 118.	1.8	1
466	N2 year in review and message from the editor to our reviewers. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e525.	6.0	1
467	Functional connectivity alterations of striato-cortical circuits in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1469-1470.	3.0	1
468	N2 year in review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e644.	6.0	1

#	ARTICLE	IF	CITATIONS
469	A novel investigation method for axonal damage in neuromyelitis optica spectrum disorder: In vivo corneal confocal microscopy. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732199806.	1.0	1
470	The German Healthcare System. Advances in Predictive, Preventive and Personalised Medicine, 2012, , 45-67.	0.6	1
471	Flammer Syndrome and Autoimmune Inflammatory Conditions of the Central Nervous System: Multifactorial Interrelations. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 145-163.	0.6	1
472	Diagnostic efficacy of the magnetic resonance T1w/T2w ratio for the middle cerebellar peduncle in multiple system atrophy and spinocerebellar ataxia: A preliminary study. PLoS ONE, 2022, 17, e0267024.	2.5	1
473	Fatigue and sleep disorders in multiple sclerosis: is obstructive sleep apnea a link?. Sleep and Breathing, 2012, 16, 949-950.	1.7	0
474	Optical coherence tomography in neurodegenerative and other neurologic diseases. , 0, , 128-144.		0
475	Does Nrf2 help nerves to survive?. Neurology: Neuroimmunology and Neuroinflammation, 2015, 2, e105.	6.0	0
476	Iridodonesis as a cause of recurrent vertigo. Neurology, 2015, 85, 1353-1353.	1.1	0
477	Ranking of Dystonia Severity by Pairwise Video Comparison. Movement Disorders Clinical Practice, 2016, 3, 587-595.	1.5	0
478	What is the future of proof of concept studies in multiple sclerosis?. Lancet Neurology, The, 2016, 15, 1107-1109.	10.2	0
479	Venoplasty in MS. Neurology, 2018, 91, 815-816.	1.1	0
480	Progressive Multiple Sclerosis (SP and PP MS). , 2016, , 135-150.		0